Sarepta Therapeutics Inc., of Cambridge, Mass., said the initial purchasers of its convertible senior unsecured notes that will mature on Nov. 15, 2024, have exercised their option to purchase an additional $95 million in notes, which is expected to close on Nov. 14, 2017.